Roche AGObesityRoche moves obesity asset CT-388 into Phase IIISwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by … more ➔
MAES-AREA-EnglosRestructuringGenfit SA discontinues lead programmeLille-based Genfit SA has discontinued Phase II development of its lead drug candidate VS-01, a liposomal ammonia scavenger designed to prevent organ failure in acute chronic liver failure (ACLF). The … more ➔
wikipedia - PyMOL rendering of PDBFinancingMondego Bio kicks off with Series A financingLisbon’s immuno-oncology company Mondego Bio Lda has left stealth mode through a Series A financing led by Biovance Capital, supported by OrbiMed and Torrey Pines. more ➔
Henk Vrieselaar - stock.adobe.com M&ARoche acquires 89bio for US$3.5bnRoche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis … more ➔
Adobe stock photos - nadiaPartnershipCSL backs VarmX in US$2.2bn dealCSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001. more ➔
adobe stock photos - kemolSeries A financingEnhanced Genomics raises US$19mBritish Enhanced Genomics Ltd has extended its Series A funding to US$19m. Investors include BGF, Parkwalk, and Meltwind. more ➔
Rosa Therapeutics IncPartnershipsMonte Rosa Therapeutics and Novartis agree on second billion-dollar dealMonte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders. … more ➔
FDADrug evaluationTrump dismantles FDA expert committeesThe FDA under President Trump is heading for a radical break with decades of practice: the external advisory committees that have long served as critical checks in approval decisions are to be largely … more ➔
adobe stock photo - TokoStatisticsUK pharma lobby warns of crisis in British life sciencesThe Association of the British Pharmaceutical Industry (ABPI) has warned that the UK could miss its target of becoming the number one in European life sciences by 2030. more ➔
Alchemab Therapeutics LtdFinancingAlchemab Therapeutics reports US$32m Series A extensionBritish antibody specialist Alchemab Therapeutics Ltd has secured a US$32m Series A extension after it completing preclinical development of ATLX-1282 and starting a Phase I clinical trial. more ➔
Roche AG
MAES-AREA-Englos
wikipedia - PyMOL rendering of PDB
Henk Vrieselaar - stock.adobe.com 
Adobe stock photos - nadia
adobe stock photos - kemol
Rosa Therapeutics Inc
FDA
adobe stock photo - Toko
Alchemab Therapeutics Ltd